Switch to:

BridgeBio Pharma Long-Term Debt

: $471.89 Mil (As of Sep. 2020)
View and export this data going back to 2019. Start your Free Trial

BridgeBio Pharma's Long-Term Debt for the quarter that ended in Sep. 2020 was $471.89 Mil.

BridgeBio Pharma's quarterly Long-Term Debt increased from Mar. 2020 ($461.34 Mil) to Jun. 2020 ($466.56 Mil) and increased from Jun. 2020 ($466.56 Mil) to Sep. 2020 ($471.89 Mil).

BridgeBio Pharma's annual Long-Term Debt increased from Dec. 2017 ($0.00 Mil) to Dec. 2018 ($54.51 Mil) and increased from Dec. 2018 ($54.51 Mil) to Dec. 2019 ($91.79 Mil).

BridgeBio Pharma Long-Term Debt Historical Data

* All numbers are in millions except for per share data and ratio. All numbers are in their local exchange's currency.

* Premium members only.

BridgeBio Pharma Annual Data
Dec17 Dec18 Dec19
Long-Term Debt 0.00 54.51 91.79

BridgeBio Pharma Quarterly Data
Dec17 Mar18 Jun18 Sep18 Dec18 Mar19 Jun19 Sep19 Dec19 Mar20 Jun20 Sep20
Long-Term Debt Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 75.02 91.79 461.34 466.56 471.89

BridgeBio Pharma  (NAS:BBIO) Long-Term Debt Explanation

Long-Term Debt is the sum of the carrying values as of the balance sheet date of all long-term debt, which is debt initially having maturities due after one year or beyond the operating cycle, if longer, but excluding the portions thereof scheduled to be repaid within one year or the normal operating cycle, if longer. Long-Term Debt includes notes payable, bonds payable, mortgage loans, convertible debt, subordinated debt and other types of long term debt.

BridgeBio Pharma Long-Term Debt Related Terms

BridgeBio Pharma Long-Term Debt Headlines

No Headline

Get WordPress Plugins for easy affiliate links on Stock Tickers and Guru Names | Earn affiliate commissions by embedding GuruFocus Charts
GuruFocus Affiliate Program: Earn up to $400 per referral. ( Learn More)